αvβ3 Integrin Antagonists Enhance Chemotherapy Response in an Orthotopic Pancreatic Cancer Model

• Main Authors: Melis Debreli Coskun (Author), Thangirala Sudha (Author), Dhruba J. Bharali (Author), Serap Celikler (Author), Paul J. Davis (Author), Shaker A. Mousa (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic cancer decreases survival time and quality of life because of drug resistance and peripheral neuropathy during conventional treatment. This study was undertaken to investigate whether αvβ3 integrin receptor antagonist compounds NDAT and XT199 can suppress the development of cisplatin resi...